Tag: Platform

Medtronic and NVIDIA Collaborate to Build AI Platform for Medical Devices

Integrating NVIDIA Technologies Into Medtronic’s Authentic-Time AI Endoscopy Machine to Assist Enhance Affected person Treatment and Results

GTC—NVIDIA nowadays announced that it is collaborating with Medtronic, the world’s major health care technological innovation provider, to speed up the improvement of AI in the healthcare procedure and bring new AI-dependent alternatives into affected individual care.

The companies will combine NVIDIA healthcare and edge AI systems into Medtronic’s GI Genius™ clever endoscopy module, created and manufactured by Cosmo Prescribed drugs. GI Genius is the very first Food and drug administration-cleared, AI-assisted colonoscopy resource to aid physicians detect polyps that can direct to colorectal cancer.

GI Genius has been built to host a suite of AI algorithms and integrating the NVIDIA Clara™ health care platform could let Medtronic to scale progress of algorithms for authentic-time processes, perhaps accelerating AI innovation for far better affected individual care.

“Artificial intelligence is a impressive software that can improve the velocity, performance and effectiveness of international overall health devices,” explained Kimberly Powell, vice president of health care at NVIDIA. “We’re collaborating with Medtronic to speed up AI innovation by enabling a software program-outlined business product, with the objective of increasing scientific decision earning, reducing professional medical variability and driving improved affected individual results.”

“We think that collaborating with AI providers and developers like NVIDIA and Cosmo is necessary to driving innovation within the health care product business,” stated Giovanni Di Napoli, president of Gastrointestinal Small business at Medtronic. “We are committed to functioning with the ideal and brightest minds in the subject of AI to acquire new systems that can increase client results and remodel the way we technique healthcare.”

Medtronic intends to combine NVIDIA Holoscan — a actual-time AI computing application system for making clinical devices — and NVIDIA IGX, an industrial-grade edge AI hardware platform, to run with its GI Genius AI-assisted colonoscopy method to help medical professionals with AI-enhanced diagnostic photos. Holoscan will help deliver the most current AI purposes into clinical options by delivering the entire-stack infrastructure necessary for scalable, application-defined processing of streaming info at the edge.

The NVIDIA Holoscan and IGX system helps make program-outlined healthcare devices feasible by enabling builders to successfully teach and validate AI styles in just the Cosmo Innovation Centre, and then host the AI-driven applications on Medtronic’s GI Genius AI Access™ Platform, a market for application-as-a-healthcare-machine (SaMD) purposes.

The to start with GI Genius units developed with the NVIDIA know-how will be offered later this yr.

Enjoy NVIDIA founder and CEO Jensen Huang explore the Medtronic collaboration in his GTC keynote.

Neuralink competitor launches platform to accelerate medical innovation

A Science employee at work in the lab.

Courtesy: Science Corporation

Biotechnology startup and Neuralink competitor Science on Monday launched a new platform that aims to make it easier for other companies to quickly develop and produce medical devices. 

The platform, called Science Foundry, allows companies to utilize and build upon Science’s internal infrastructure by offering access to more than 80 of its tools and services, like the company’s thin-film electrode technologies.

related investing news

Neuralink competitor launches platform to accelerate medical innovation

CNBC Pro

The cost of the technology required to develop medical devices is often “prohibitive” for early-stage startups, Science Co-Founder and CEO Max Hodak told CNBC in an interview. Individual tools can cost anywhere from $200,000 to $2 million, and Hodak said companies could easily spend hundreds of millions building a manufacturing line. 

For many startups, that cost is too much to bear, but Hodak is hoping Science Foundry can help.

“Hopefully, we bring down the barriers to innovation,” Hodak said. “There’s a bunch of smart people out there that have a bunch of different ideas than the ones that we have, and we would like to enable them.” 

Science is part of the growing brain-computer interface, or BCI, industry. A BCI is a system that deciphers brain signals and translates them into commands for external technologies. Perhaps the best-known name in the space is Neuralink, thanks to the high profile of founder Elon Musk, who is also the CEO of Tesla, SpaceX and Twitter.

Hodak co-founded Neuralink and served as the company’s president until he announced his departure in 2021. At Neuralink, Hodak helped develop a BCI system that is designed to be implanted directly into the brain, but at Science, he is working on an implant that doesn’t directly touch the brain at all.

Science’s flagship BCI system is the Science Eye– a visual prosthesis that aims to help patients with two forms of serious blindness restore some visual input to their brains. 

The Science Eye relies on a thin, flexible micro-LED array that is surgically implanted over the retina. The implant controls a group of light-sensitive cells in the optic nerve that Science alters through a form of optogenetic gene therapy. When one pixel is turned on in the array, a cell is turned on in the optic nerve, which can be used to drive the nerve and send vision into the brain. 

Science’s implant is powered by special glasses that are outfitted with tiny sensors and cameras. The LED array translates the images it receives from the glasses and sends them up to the optic nerve. 

Hodak said the resulting images will look different than what people with healthy eyes are used to – at least for the first iteration of the technology – but that it will be very restorative for patients with no light sensitivity. Eventually, he said thinks Science will be able to reproduce high-resolution color vision. 

Science has been testing the technology in rabbits, and Hodak said the company hopes to eventually conduct trials with human patients as soon as next year.

The company’s new platform Science Foundry aims to support companies working on similarly ambitious ideas. Hodak said he expects to see demand from other neurotechnology companies, but that other medical technology startups and even quantum computing companies represent growth opportunities. 

The cost of using Science Foundry is comparable to the cost of working with academic facilities, which are “cheap to get started,” Hodak said. But while academic facilities typically do not allow companies to test devices on patients or sell them on the market, Hodak said it will be easier for Science Foundry customers to commercialize their products.

Hodak said the platform will benefit Science and the broader industry as a whole.

“This enables us to afford larger-scale and more capabilities that then we can use to enable the community and ourselves even further,” he said. 

Trainerize Powered by ABC Fitness Voted as the #1 Platform of 2022 by Personal Trainers and Coaches

G2, the largest tech marketplace, named Trainerize the leading software for personal trainers for each season in 2022

VANCOUVER, BC, March 2, 2023 /PRNewswire/ — Trainerize, the fitness coaching software empowering personal trainers and fitness businesses to better engage with their members, is delighted to announce its recognition as the best personal training software from the community, marketplace, business and review platform, G2 all throughout 2022.

Trainerize Powered by ABC Fitness Voted as the #1 Platform of 2022 by Personal Trainers and Coaches

Trainerize

Trainerize was the winner of G2’s award for Best Personal Training Software in every season in 2022, claiming the #1 position in Winter, Spring, Summer, and Fall.

The criteria for this particular recognition consists of review scores from the G2 user community and data aggregated from online sources and social networks. The points process takes into account how well the fitness software can empower fitness professionals to keep track of client information, create training and nutrition plans, schedule meetings/training sessions, and easily manage online client payments.

Trainerize exceeded all of the necessary criteria and proved to be an excellent solution for coaches to manage client fitness, nutrition and habit programming in one place. In addition, Trainerize aids its users with keeping track of their clients’ progress and increasing client engagement.

Throughout 2022, the Trainerize platform was also awarded with several other badges from G2 under various categories, including: Best Usability, Best Results, Best Relationship and Users Most Likely To Recommend.

Speaking after G2’s Winter award winners were announced, Trainerize Platform President, Sharad Mohan said, “for Trainerize to be recognized as a Leader in Personal Training Software is not only gratifying, but extremely motivating. This award is based on real-life consumer reviews and feedback, which not only makes it so much more meaningful, but also tells us that what we’re doing at Trainerize is working. So we’re going to keep doing it—and more. We’ll keep delivering the kind of platform personal trainers and fitness businesses both want and need—and that their clients and members love using.”

About Trainerize

Trainerize is a client engagement mobile app and software that allows fitness businesses and fitness professionals to expand their reach beyond their physical spaces, better connect with clientele, build meaningful relationships, and digitize the training experience. Fitness businesses use Trainerize to boost member engagement through digital services as well as attract new members by tapping into the market of online training. To learn more, visit www.trainerize.com.

About ABC Fitness Solutions

ABC Fitness (ABC) is the market leading software and services provider for fitness businesses globally. Building upon a legacy of excellence, ABC enables fitness operators of all sizes, anywhere in the world to transform their vision of fitness into reality. Whether a boutique studio, international franchise, regional club chain, local gym, or personal trainer, ABC provides the industry insights, technology, and innovation to partner for growth long-term. Our club management solutions simplify business operations while unveiling opportunities for further development and evolution. We are the only software provider to be able to support fitness businesses from conception all the way through to high-scale growth internationally, delivering reliability and quality at scale.

Founded in 1981, ABC has grown its global capabilities and expanded its integrated solution suite through the development of best-of-breed platforms such as IGNITE, Trainerize, Glofox, EVO, as well as other leading solutions. ABC helps over 35 million members around the world and processes over $8.8B+ in payments annually for 24,000 clubs in over 92 countries. ABC Fitness Solutions is a Thoma Bravo portfolio company; a leading private equity firm focused on investing in high-growth software and technology companies.  Learn more at abcfitness.com or thomabravo.com.

Media Contact
Laura Dunlop
Marketing Director, Trainerize
778.953.2489
354793@email4pr.com

Trainerize - Best Coaching App

Trainerize – Best Coaching App

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/trainerize-powered-by-abc-fitness-voted-as-the-1-platform-of-2022-by-personal-trainers-and-coaches-301760942.html

SOURCE Trainerize

Tumor organoid biobank-new platform for medical research

  • Pan, W. et al. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs. Front. Immunol. 13, 982486. https://doi.org/10.3389/fimmu.2022.982486 (2022).

    Article 
    CAS 

    Google Scholar     

  • Wang, X. et al. Cross-talk of four types of RNA modification proteins with adenosine reveals the landscape of multivariate prognostic patterns in breast cancer. Front. Genet. 13, 943378. https://doi.org/10.3389/fgene.2022.943378 (2022).

    Article 
    CAS 

    Google Scholar     

  • Sweed, D. et al. The clinicopathological and prognostic factors of hepatocellular carcinoma: A 10-year tertiary center experience in Egypt. World J. Surg. Oncol. 20, 298. https://doi.org/10.1186/s12957-022-02764-2 (2022).

    Article 

    Google Scholar     

  • Cheng, C., Feng, X., Li, X. & Wu, M. Robust analysis of cancer heterogeneity for high-dimensional data. Stat. Med. 41, 5448–5462. https://doi.org/10.1002/sim.9578 (2022).

    Article 

    Google Scholar     

  • Abdelraouf, E. M. et al. Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression. Life Sci. 308, 120967. https://doi.org/10.1016/j.lfs.2022.120967 (2022).

    Article 
    CAS 

    Google Scholar     

  • Elbadawy, M. et al. Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids. Biomed. Pharmacother. 142, 112043. https://doi.org/10.1016/j.biopha.2021.112043 (2021).

    Article 
    CAS 

    Google Scholar     

  • Elbadawy, M. et al. Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism. Cancer Biol. Ther. 22, 357–371. https://doi.org/10.1080/15384047.2021.1919004 (2021).

    Article 
    CAS 

    Google Scholar     

  • Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324–338. https://doi.org/10.1016/j.cell.2014.12.021 (2015).

    Article 
    CAS 

    Google Scholar     

  • Clevers, H. Modeling development and disease with organoids. Cell 165, 1586–1597. https://doi.org/10.1016/j.cell.2016.05.082 (2016).

    Article 
    CAS 

    Google Scholar     

  • Lancaster, M. A. & Huch, M. Disease modelling in human organoids. Dis. Model Mech. 12, dmm039347. https://doi.org/10.1242/dmm.039347 (2019).

    Article 
    CAS 

    Google Scholar     

  • Huang, Y. et al. Air pollution, genetic factors, and the risk of lung cancer: A prospective study in the UK biobank. Am. J. Respir. Crit. Care Med. 204, 817–825. https://doi.org/10.1164/rccm.202011-4063OC (2021).

    Article 
    CAS 

    Google Scholar     

  • Jacob, F. et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell 180, 188-204.e22. https://doi.org/10.1016/j.cell.2019.11.036 (2020).

    Article 
    CAS 

    Google Scholar     

  • Said, M. A., Verweij, N. & van der Harst, P. Associations of combined genetic and lifestyle risks with incident cardiovascular disease and diabetes in the UK Biobank study. JAMA Cardiol. 3, 693–702. https://doi.org/10.1001/jamacardio.2018.1717 (2018).

    Article 

    Google Scholar     

  • Muller, D. C., Johansson, M. & Brennan, P. Lung cancer risk prediction model incorporating lung function: Development and validation in the UK Biobank prospective cohort study. J. Clin. Oncol. 35, 861–869. https://doi.org/10.1200/JCO.2016.69.2467 (2017).

    Article 

    Google Scholar     

  • Wang, Q. L., Ness-Jensen, E., Santoni, G., Xie, S. H. & Lagergren, J. Development and validation of a risk prediction model for esophageal squamous cell carcinoma using cohort studies. Am. J. Gastroenterol. 116, 683–691. https://doi.org/10.14309/ajg.0000000000001094 (2021).

    Article 

    Google Scholar     

  • Takahashi, Y. et al. A refined culture system for human induced pluripotent stem cell-derived intestinal epithelial organoids. Stem Cell Rep. 10, 314–328. https://doi.org/10.1016/j.stemcr.2017.11.004 (2018).

    Article 
    CAS 

    Google Scholar     

  • Noguchi, T. K. et al. Generation of stomach tissue from mouse embryonic stem cells. Nat. Cell Biol. 17, 984–993. https://doi.org/10.1038/ncb3200 (2015).

    Article 
    CAS 

    Google Scholar     

  • McCracken, K. W., Howell, J. C., Wells, J. M. & Spence, J. R. Generating human intestinal tissue from pluripotent stem cells in vitro. Nat. Protoc. 6, 1920–1928. https://doi.org/10.1038/nprot.2011.410 (2011).

    Article 
    CAS 

    Google Scholar     

  • Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262–265. https://doi.org/10.1038/nature07935 (2009).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933–945. https://doi.org/10.1016/j.cell.2015.03.053 (2015).

    Article 
    CAS 

    Google Scholar     

  • Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920–926. https://doi.org/10.1126/science.aao2774 (2018).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Fujii, M. et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell 18, 827–838. https://doi.org/10.1016/j.stem.2016.04.003 (2016).

    Article 
    CAS 

    Google Scholar     

  • Kraiczy, J. et al. DNA methylation defines regional identity of human intestinal epithelial organoids and undergoes dynamic changes during development. Gut 68, 49–61. https://doi.org/10.1136/gutjnl-2017-314817 (2019).

    Article 
    CAS 

    Google Scholar     

  • Zachos, N. C. et al. Human enteroids/colonoids and intestinal organoids functionally recapitulate normal intestinal physiology and pathophysiology. J. Biol. Chem. 291, 3759–3766. https://doi.org/10.1074/jbc.R114.635995 (2016).

    Article 
    CAS 

    Google Scholar     

  • Saksena, S. Nonpharmacologic therapy for tachyarrhythmias: The tower of Babel revisited?. Pacing Clin. Electrophysiol. 11, 93–97. https://doi.org/10.1111/j.1540-8159.1988.tb03932.x (1988).

    Article 
    CAS 

    Google Scholar     

  • Xu, R., Zhou, X., Wang, S. & Trinkle, C. Tumor organoid models in precision medicine and investigating cancer-stromal interactions. Pharmacol. Ther. 218, 107668. https://doi.org/10.1016/j.pharmthera.2020.107668 (2021).

    Article 
    CAS 

    Google Scholar     

  • Kim, J., Koo, B. K. & Knoblich, J. A. Human organoids: Model systems for human biology and medicine. Nat. Rev. Mol. Cell Biol. 21, 571–584. https://doi.org/10.1038/s41580-020-0259-3 (2020).

    Article 
    CAS 

    Google Scholar     

  • Dekkers, J. F. et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci. Transl. Med. 8, 344ra84. https://doi.org/10.1126/scitranslmed.aad8278 (2016).

    Article 
    CAS 

    Google Scholar     

  • Sugimoto, S. et al. Reconstruction of the human colon epithelium in vivo. Cell Stem Cell. 22, 171-176.e5. https://doi.org/10.1016/j.stem.2017.11.012 (2018).

    Article 
    CAS 

    Google Scholar     

  • Driehuis, E., Kretzschmar, K. & Clevers, H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat. Protoc. 15, 3380–3409. https://doi.org/10.1038/s41596-020-0379-4 (2020).

    Article 
    CAS 

    Google Scholar     

  • Maenhoudt, N. et al. Developing organoids from ovarian cancer as experimental and preclinical models. Stem Cell Rep. 14, 717–729. https://doi.org/10.1016/j.stemcr.2020.03.004 (2020).

    Article 
    CAS 

    Google Scholar     

  • Lu, Z., Nie, B., Zhai, W. & Hu, Z. Delineating the longitudinal tumor evolution using organoid models. J. Genet. Genom. 48, 560–570. https://doi.org/10.1016/j.jgg.2021.06.010 (2021).

    Article 

    Google Scholar     

  • Wang, Z. et al. The Fibrillin-1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells. Cancer Commun. 42, 245–265. https://doi.org/10.1002/cac2.12274 (2022).

    Article 
    CAS 

    Google Scholar     

  • Rao, S., Hossain, T. & Mahmoudi, T. 3D human liver organoids: An in vitro platform to investigate HBV infection, replication and liver tumorigenesis. Cancer Lett. 506, 35–44. https://doi.org/10.1016/j.canlet.2021.02.024 (2021).

    Article 
    CAS 

    Google Scholar     

  • Yoshida, S., Miwa, H., Kawachi, T., Kume, S. & Takahashi, K. Generation of intestinal organoids derived from human pluripotent stem cells for drug testing. Sci. Rep. 10, 5989. https://doi.org/10.1038/s41598-020-63151-z (2020).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • d’Aldebert, E. et al. Characterization of human colon organoids from inflammatory bowel disease patients. Front. Cell Dev. Biol. 8, 363. https://doi.org/10.3389/fcell.2020.00363 (2020).

    Article 

    Google Scholar     

  • Min, S., Kim, S. & Cho, S. W. Gastrointestinal tract modeling using organoids engineered with cellular and microbiota niches. Exp. Mol. Med. 52, 227–237. https://doi.org/10.1038/s12276-020-0386-0 (2020).

    Article 
    CAS 

    Google Scholar     

  • den Hertog, J. & de Laat, S. W. Hubrecht Institute Centennial: From embryos to stem cells. Dev. Biol. 428, 261–263. https://doi.org/10.1016/j.ydbio.2017.02.004 (2017).

    Article 
    CAS 

    Google Scholar     

  • Rabouille, C. & Deschamps, J. On the shoulders of Hubrecht: From embryos to stem cells. Dev. Biol. 428, 264–272. https://doi.org/10.1016/j.ydbio.2016.10.005 (2017).

    Article 
    CAS 

    Google Scholar     

  • Reddelle, A. K. Innovation in brain tumor treatment: A nurse perspective. Cureus 13, e20037. https://doi.org/10.7759/cureus.20037 (2021).

    Article 

    Google Scholar     

  • Ostrom, Q. T. et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 20, 1–86. https://doi.org/10.1093/neuonc/noy131 (2018).

    Article 

    Google Scholar     

  • Ostrom, Q. T., Cioffi, G., Waite, K., Kruchko, C. & Barnholtz-Sloan, J. S. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol. 23, 1–105. https://doi.org/10.1093/neuonc/noab200 (2018).

    Article 

    Google Scholar     

  • Yang, P. et al. Management and survival rates in patients with glioma in China (2004–2010): A retrospective study from a single-institution. J. Neurooncol. 113, 259–266. https://doi.org/10.1007/s11060-013-1103-9 (2013).

    Article 
    CAS 

    Google Scholar     

  • Helguera, G. et al. Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry. J. Immunol. Methods 368, 54–63. https://doi.org/10.1016/j.jim.2011.03.003 (2011).

    Article 
    CAS 

    Google Scholar     

  • Darmanis, S. et al. Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep. 21, 1399–1410. https://doi.org/10.1016/j.celrep.2017.10.030 (2017).

    Article 
    CAS 

    Google Scholar     

  • Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835-849.e21. https://doi.org/10.1016/j.cell.2019.06.024 (2019).

    Article 
    CAS 

    Google Scholar     

  • Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401. https://doi.org/10.1126/science.1254257 (2014).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Mandel, J. J. et al. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 20, 113–122. https://doi.org/10.1093/neuonc/nox144 (2018).

    Article 
    CAS 

    Google Scholar     

  • Abdullah, K. G. et al. Establishment of patient-derived organoid models of lower-grade glioma. Neuro Oncol. 24, 612–623. https://doi.org/10.1093/neuonc/noab273 (2022).

    Article 
    CAS 

    Google Scholar     

  • Si, Y. F. et al. A study on the value of narrow-band imaging (NBI) for the general investigation of a high-risk population of nasopharyngeal carcinoma (NPC). World J. Surg. Oncol. 16, 126. https://doi.org/10.1186/s12957-018-1423-5 (2018).

    Article 

    Google Scholar     

  • Chen, Y. P. et al. Nasopharyngeal carcinoma. Lancet 394, 64–80. https://doi.org/10.1016/S0140-6736(19)30956-0 (2019).

    Article 

    Google Scholar     

  • Thamboo, A., Patel, V. S. & Hwang, P. H. 5-year outcomes of salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma. J. Otolaryngol. Head Neck Surg. 50, 12. https://doi.org/10.1186/s40463-020-00482-x (2021).

    Article 

    Google Scholar     

  • Chen, W. et al. Long noncoding RNA cytoskeleton regulator RNA promotes cell invasion and metastasis by titrating miR-613 to regulate ANXA2 in nasopharyngeal carcinoma. Cancer Med. 9, 1209–1219. https://doi.org/10.1002/cam4.2778 (2020).

    Article 
    CAS 

    Google Scholar     

  • Wang, X. W. et al. Establishment of a patient-derived organoid model and living biobank for nasopharyngeal carcinoma. Ann. Transl. Med. 10, 526. https://doi.org/10.21037/atm-22-1076 (2022).

    Article 
    CAS 

    Google Scholar     

  • Yan, H. H. N. et al. Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles. Gut 69, 2165–2179. https://doi.org/10.1136/gutjnl-2019-320019 (2020).

    Article 
    CAS 

    Google Scholar     

  • Yao, Y. et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell 26, 17-26.e6. https://doi.org/10.1016/j.stem.2019.10.010 (2020).

    Article 
    CAS 

    Google Scholar     

  • Geevimaan, K. et al. Patient-derived organoid serves as a platform for personalized chemotherapy in advanced colorectal cancer patients. Front. Oncol. 12, 883437. https://doi.org/10.3389/fonc.2022.883437 (2022).

    Article 

    Google Scholar     

  • Mo, S. et al. Patient-derived organoids from colorectal cancer with paired liver metastasis reveal tumor heterogeneity and predict response to chemotherapy. Adv. Sci. 9, e2204097. https://doi.org/10.1002/advs.202204097 (2022).

    Article 
    CAS 

    Google Scholar     

  • Laoukili, J. et al. Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity. Br. J. Cancer 126, 1824–1833. https://doi.org/10.1038/s41416-022-01742-5 (2022).

    Article 
    CAS 

    Google Scholar     

  • Usui, T. et al. Hedgehog signals mediate anti-cancer drug resistance in three-dimensional primary colorectal cancer organoid culture. Int. J. Mol. Sci. 19, 1098. https://doi.org/10.3390/ijms19041098 (2018).

    Article 
    CAS 

    Google Scholar     

  • Yao, L. et al. Application of tumoroids derived from advanced colorectal cancer patients to predict individual response to chemotherapy. J. Chemother. https://doi.org/10.1080/1120009X.2022.2045827 (2022).

    Article 

    Google Scholar     

  • Herpers, B. et al. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nat. Cancer 3, 418–436. https://doi.org/10.1038/s43018-022-00359-0 (2022).

    Article 
    CAS 

    Google Scholar     

  • Yan, H. H. N. et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell 23, 882-897.e11. https://doi.org/10.1016/j.stem.2018.09.016 (2018).

    Article 
    CAS 

    Google Scholar     

  • Schütte, M. et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat. Commun. 8, 14262. https://doi.org/10.1038/ncomms14262 (2017).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Mohammadian, M., Allah Bakeshei, K. & Mohammadian-Hafshejani, A. International epidemiology of liver cancer: Geographical distribution, secular trends and predicting the future. J. Prev. Med. Hyg. 61, E259–E289. https://doi.org/10.15167/2421-4248/jpmh2020.61.2.1244 (2020).

    Article 
    CAS 

    Google Scholar     

  • Nuciforo, S. et al. Organoid models of human liver cancers derived from tumor needle biopsies. Cell Rep. 24, 1363–1376. https://doi.org/10.1016/j.celrep.2018.07.001 (2018).

    Article 
    CAS 

    Google Scholar     

  • Rawla, P., Sunkara, T. & Gaduputi, V. Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J. Oncol. 10, 10–27. https://doi.org/10.14740/wjon1166 (2019).

    Article 

    Google Scholar     

  • Saad, A. M., Turk, T., Al-Husseini, M. J. & Abdel-Rahman, O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer 18, 688. https://doi.org/10.1186/s12885-018-4610-4 (2018).

    Article 

    Google Scholar     

  • Patel, N., Khorolsky, C. & Benipal, B. Incidence of pancreatic adenocarcinoma in the United States from 2001 to 2015: A United States cancer statistics analysis of 50 states. Cureus 10, e3796. https://doi.org/10.7759/cureus.3796 (2018).

    Article 

    Google Scholar     

  • Gordon-Dseagu, V. L., Devesa, S. S., Goggins, M. & Stolzenberg-Solomon, R. Pancreatic cancer incidence trends: Evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int. J. Epidemiol. 47, 427–439. https://doi.org/10.1093/ije/dyx232 (2018).

    Article 

    Google Scholar     

  • Wong, M. C. S. et al. Global temporal patterns of pancreatic cancer and association with socioeconomic development. Sci. Rep. 7, 3165. https://doi.org/10.1038/s41598-017-02997-2 (2017).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Farrell, J. J. Prevalence, diagnosis and management of pancreatic cystic neoplasms: Current status and future directions. Gut Liver 9, 571–589. https://doi.org/10.5009/gnl15063 (2015).

    Article 

    Google Scholar     

  • Basar, O. & Brugge, W. R. My treatment approach: Pancreatic cysts. Mayo Clin. Proc. 92, 1519–1531. https://doi.org/10.1016/j.mayocp.2017.06.017 (2017).

    Article 

    Google Scholar     

  • Beato, F. et al. Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms of the pancreas. Lab. Invest. 101, 204–217. https://doi.org/10.1038/s41374-020-00494-1 (2021).

    Article 

    Google Scholar     

  • Huang, B. et al. Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. J. Pathol. 252, 252–262. https://doi.org/10.1002/path.5515 (2020).

    Article 
    CAS 

    Google Scholar     

  • Hirt, C. K. et al. Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment. Cell Genom. 2, 100095. https://doi.org/10.1016/j.xgen.2022.100095 (2022).

    Article 
    CAS 

    Google Scholar     

  • Demyan, L. et al. Pancreatic cancer patient-derived organoids can predict response to neoadjuvant chemotherapy. Ann. Surg. 276, 450–462. https://doi.org/10.1097/SLA.0000000000005558 (2022).

    Article 

    Google Scholar     

  • Driehuis, E. et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc. Natl. Acad. Sci. U S A 116, 26580–26590. https://doi.org/10.1073/pnas.1911273116 (2019).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Vaes, R. D. W. et al. Generation and initial characterization of novel tumour organoid models to study human pancreatic cancer-induced cachexia. J. Cachexia Sarcopenia Muscle 11, 1509–1524. https://doi.org/10.1002/jcsm.12627 (2020).

    Article 

    Google Scholar     

  • Kawasaki, K. et al. An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping. Cell 183, 1420-1435.e21. https://doi.org/10.1016/j.cell.2020.10.023 (2020).

    Article 
    CAS 

    Google Scholar     

  • Bray, F. et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424. https://doi.org/10.3322/caac.21492(2018) (2018).

    Article 

    Google Scholar     

  • Sun, X., Bao, J. & Shao, Y. Mathematical modeling of therapy-induced cancer drug resistance: Connecting cancer mechanisms to population survival rates. Sci. Rep. 6, 22498. https://doi.org/10.1038/srep22498 (2016).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Kaur, P., Garg, T., Rath, G., Murthy, R. S. & Goyal, A. K. Surfactant-based drug delivery systems for treating drug-resistant lung cancer. Drug Deliv. 23, 727–738. https://doi.org/10.3109/10717544.2014.935530 (2016).

    Article 
    CAS 

    Google Scholar     

  • Zhang, Z. et al. Establishment of patient-derived tumor spheroids for non-small cell lung cancer. PLoS ONE 13, e0194016. https://doi.org/10.1371/journal.pone.0194016 (2018).

    Article 
    CAS 

    Google Scholar     

  • Kim, S. Y. et al. Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma. Clin. Cancer Res. 27, 4397–4409. https://doi.org/10.1158/1078-0432.CCR-20-5026 (2021).

    Article 
    CAS 

    Google Scholar     

  • Li, Y. F. et al. Patient-derived organoids of non-small cells lung cancer and their application for drug screening. Neoplasma 67, 430–437. https://doi.org/10.4149/neo_2020_190417N346 (2020).

    Article 
    CAS 

    Google Scholar     

  • Calandrini, C. et al. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nat. Commun. 11, 1310. https://doi.org/10.1038/s41467-020-15155-6 (2020).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Kamat, A. M. et al. Bladder cancer. Lancet 388, 2796–2810. https://doi.org/10.1016/S0140-6736(16)30512-8 (2016).

    Article 

    Google Scholar     

  • Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25–41. https://doi.org/10.1038/nrc3817 (2015).

    Article 
    CAS 

    Google Scholar     

  • Lerner, S. P. et al. Summary and recommendations from the national cancer institute’s clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer. Bladder Cancer 2, 165–202. https://doi.org/10.3233/BLC-160053 (2016).

    Article 

    Google Scholar     

  • Lee, S. H. et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell 173, 515-528.e17. https://doi.org/10.1016/j.cell.2018.03.017 (2018).

    Article 
    CAS 

    Google Scholar     

  • Weber, C. A biobank for bladder cancer. Nat. Cell Biol. 20, 634. https://doi.org/10.1038/s41556-018-0114-3 (2018).

    Article 
    CAS 

    Google Scholar     

  • Mullenders, J. et al. Mouse and human urothelial cancer organoids: A tool for bladder cancer research. Proc. Natl. Acad. Sci. U S A 116, 4567–4574. https://doi.org/10.1073/pnas.1803595116 (2019).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Elbadawy, M. et al. Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture. Cancer Sci. 110, 2806–2821. https://doi.org/10.1111/cas.14118 (2019).

    Article 
    CAS 

    Google Scholar     

  • Elbadawy, M. et al. Establishment of an experimental model of normal dog bladder organoid using a three-dimensional culture method. Biomed. Pharmacother. 151, 113105. https://doi.org/10.1016/j.biopha.2022.113105 (2022).

    Article 

    Google Scholar     

  • Nuhn, P. et al. Update on systemic prostate cancer therapies: Management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur. Urol. 75, 88–99. https://doi.org/10.1016/j.eururo.2018.03.028 (2019).

    Article 

    Google Scholar     

  • Beshiri, M. L. et al. A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening. Clin. Cancer Res. 24, 4332–4345. https://doi.org/10.1158/1078-0432.CCR-18-0409 (2018).

    Article 
    CAS 

    Google Scholar     

  • Lõhmussaar, K. et al. Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer. Cell Stem Cell 28, 1380-1396.e6. https://doi.org/10.1016/j.stem.2021.03.012 (2021).

    Article 
    CAS 

    Google Scholar     

  • Drost, J. et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 521, 43–47. https://doi.org/10.1038/nature14415 (2015).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Matano, M. et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21, 256–262. https://doi.org/10.1038/nm.3802 (2015).

    Article 
    CAS 

    Google Scholar     

  • Ferlay, J. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386. https://doi.org/10.1002/ijc.29210 (2015).

    Article 
    CAS 

    Google Scholar     

  • Nelson, L. et al. A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity. Nat. Commun. 11, 822. https://doi.org/10.1038/s41467-020-14551-2 (2020).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • DeSantis, C. E. et al. Breast cancer statistics, 2019. CA Cancer J. Clin. 69, 438–451. https://doi.org/10.3322/caac.21583 (2019).

    Article 

    Google Scholar     

  • Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47–54. https://doi.org/10.1038/nature17676 (2016).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Dekkers, J. F. et al. Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. Nat. Protoc. 16, 1936–1965. https://doi.org/10.1038/s41596-020-00474-1 (2021).

    Article 
    CAS 

    Google Scholar     

  • Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373-386.e10. https://doi.org/10.1016/j.cell.2017.11.010 (2018).

    Article 
    CAS 

    Google Scholar     

  • Mazzucchelli, S. et al. Establishment and morphological characterization of patient-derived organoids from breast cancer. Biol. Proced. Online 21, 12. https://doi.org/10.1186/s12575-019-0099-8 (2019).

    Article 
    CAS 

    Google Scholar     

  • Shu, D. et al. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy. Ann. Med. 54, 2581–2597. https://doi.org/10.1080/07853890.2022.2122550 (2022).

    Article 
    CAS 

    Google Scholar     

  • Kim, J. et al. Genomic characteristics of triple-negative breast cancer nominate molecular subtypes that predict chemotherapy response. Mol. Cancer Res. 18, 253–263. https://doi.org/10.1158/1541-7786.MCR-19-0453 (2020).

    Article 
    CAS 

    Google Scholar     

  • Bhatia, S. et al. Patient-derived triple-negative breast cancer organoids provide robust model systems that recapitulate tumor intrinsic characteristics. Cancer Res. 82, 1174–1192. https://doi.org/10.1158/0008-5472.CAN-21-2807 (2022).

    Article 
    CAS 

    Google Scholar     

  • Francies, H. E., Barthorpe, A., McLaren-Douglas, A., Barendt, W. J. & Garnett, M. J. Drug sensitivity assays of human cancer organoid cultures. Methods Mol. Biol. 1576, 339–351. https://doi.org/10.1007/7651_2016_10 (2019).

    Article 
    CAS 

    Google Scholar     

  • Liu, H. D., Xia, B. R., Jin, M. Z. & Lou, G. Organoid of ovarian cancer: Genomic analysis and drug screening. Clin. Transl. Oncol. 22, 1240–1251. https://doi.org/10.1007/s12094-019-02276-8 (2020).

    Article 
    CAS 

    Google Scholar     

  • Pasch, C. A. et al. Patient-derived cancer organoid cultures to predict sensitivity to chemotherapy and radiation. Clin. Cancer Res. 25, 5376–5387. https://doi.org/10.1158/1078-0432.CCR-18-3590 (2019).

    Article 
    CAS 

    Google Scholar     

  • Kong, J. et al. Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients. Nat. Commun. 11, 5485. https://doi.org/10.1038/s41467-020-19313-8 (2020).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Ganesh, K. et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat. Med. 25(10), 1607–1614. https://doi.org/10.1038/s41591-019-0584-2 (2019).

    Article 
    CAS 

    Google Scholar     

  • Chew, N. J. et al. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models. Breast Cancer Res. 23, 82. https://doi.org/10.1186/s13058-021-01461-4 (2021).

    Article 
    CAS 

    Google Scholar     

  • Ding, S. et al. Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell 29, 905-917.e6. https://doi.org/10.1016/j.stem.2022.04.006 (2022).

    Article 
    CAS 

    Google Scholar     

  • Yu, C. et al. ARID1A loss derepresses a group of human endogenous retrovirus-H loci to modulate BRD4-dependent transcription. Nat. Commun. 13, 3501. https://doi.org/10.1038/s41467-022-31197-4 (2022).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Martinelli, I. et al. Brain and retinal organoids for disease modeling: The importance of in vitro blood-brain and retinal barriers studies. Cells 11, 1120. https://doi.org/10.3390/cells11071120 (2022).

    Article 
    CAS 

    Google Scholar     

  • Jabs, J. et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations. Mol. Syst. Biol. 13, 955. https://doi.org/10.15252/msb.20177697 (2017).

    Article 
    CAS 

    Google Scholar     

  • Park, S. E., Georgescu, A. & Huh, D. Organoids-on-a-chip. Science 364, 960–965. https://doi.org/10.1126/science.aaw7894 (2019).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Michl, J., Park, K. C. & Swietach, P. Evidence-based guidelines for controlling pH in mammalian live-cell culture systems. Commun. Biol. 2, 144. https://doi.org/10.1038/s42003-019-0393-7 (2019).

    Article 

    Google Scholar     

  • Gonzalez-Exposito, R. et al. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J. Immunother. Cancer 7, 101. https://doi.org/10.1186/s40425-019-0575-3 (2019).

    Article 

    Google Scholar     

  • Zhao, H., Jiang, E. & Shang, Z. 3D co-culture of cancer-associated fibroblast with oral cancer organoids. J. Dent. Res. 100, 201–208. https://doi.org/10.1177/0022034520956614 (2021).

    Article 
    CAS 

    Google Scholar     

  • Staab, J. F., Lemme-Dumit, J. M., Latanich, R., Pasetti, M. F. & Zachos, N. C. Co-culture system of human enteroids/colonoids with innate immune cells. Curr. Protoc. Immunol. 131, e113. https://doi.org/10.1002/cpim.113 (2020).

    Article 
    CAS 

    Google Scholar     

  • Morgan, K. M., Riedlinger, G. M., Rosenfeld, J., Ganesan, S. & Pine, S. R. Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine. Front. Oncol. 7, 2. https://doi.org/10.3389/fonc.2017.00002 (2017).

    Article 

    Google Scholar     

  • Luo, X. et al. Hydrogel-based colorectal cancer organoid co-culture models. Acta Biomater. 132, 461–472. https://doi.org/10.1016/j.actbio.2020.12.037 (2021).

    Article 
    CAS 

    Google Scholar     

  • Murphy, S. V. & Atala, A. 3D bioprinting of tissues and organs. Nat. Biotechnol. 32, 773–785. https://doi.org/10.1038/nbt.2958 (2014).

    Article 
    CAS 

    Google Scholar     

  • Xu, F. et al. A three-dimensional in vitro ovarian cancer coculture model using a high-throughput cell patterning platform. Biotechnol. J. 6, 204–212. https://doi.org/10.1002/biot.201000340 (2011).

    Article 
    CAS 

    Google Scholar     

  • Skardal, A. et al. Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform. Sci. Rep. 7(1), 8837. https://doi.org/10.1038/s41598-017-08879-x (2017).

    Article 
    ADS 
    CAS 

    Google Scholar     

  • Buqué, A. & Galluzzi, L. Modeling tumor immunology and immunotherapy in mice. Trends Cancer 4, 599–601. https://doi.org/10.1016/j.trecan.2018.07.003 (2018).

    Article 
    CAS 

    Google Scholar     

  • Li, Q. et al. Developing covalent protein drugs via proximity-enabled reactive therapeutics. Cell 182, 85-97.e16. https://doi.org/10.1016/j.cell.2020.05.028 (2020).

    Article 
    CAS 

    Google Scholar     

  • Curvello, R., Alves, D., Abud, H. E. & Garnier, G. A thermo-responsive collagen-nanocellulose hydrogel for the growth of intestinal organoids. Mater. Sci. Eng. C 124, 112051. https://doi.org/10.1016/j.msec.2021.112051 (2021).

    Article 
    CAS 

    Google Scholar     

  • Nagle, P. W., Plukker, J. T. M., Muijs, C. T., van Luijk, P. & Coppes, R. P. Patient-derived tumor organoids for prediction of cancer treatment response. Semin. Cancer Biol. 53, 258–264. https://doi.org/10.1016/j.semcancer.2018.06.005 (2018).

    Article 
    CAS 

    Google Scholar     

  • Hirokawa, Y. et al. Low-viscosity matrix suspension culture enables scalable analysis of patient-derived organoids and tumoroids from the large intestine. Commun. Biol. 4, 1067. https://doi.org/10.1038/s42003-021-02607-y (2021).

    Article 
    CAS 

    Google Scholar     

  • Fujii, M. et al. Human intestinal organoids maintain self-renewal capacity and cellular diversity in niche-inspired culture condition. Cell Stem Cell 23, 787-793.e6. https://doi.org/10.1016/j.stem.2018.11.016 (2018).

    Article 
    CAS 

    Google Scholar     

  • Hoffmann, K. et al. Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment. EMBO J. 39, e104013. https://doi.org/10.15252/embj.2019104013 (2020).

    Article 
    CAS 

    Google Scholar     

  • Utta, D., Heo, I. & Clevers, H. Disease modeling in stem cell-derived 3D organoid systems. Trends Mol. Med. 23, 393–410. https://doi.org/10.1016/j.molmed.2017.02.007 (2017).

    Article 
    CAS 

    Google Scholar     

  • Lensink, M. A. et al. Organoids for personalized treatment of Cystic Fibrosis: Professional perspectives on the ethics and governance of organoid biobanking. J. Cyst Fibros. 20, 443–451. https://doi.org/10.1016/j.jcf.2020.11.015 (2021).

    Article 

    Google Scholar     

  • Lensink, M. A., Boers, S. N., Gulmans, V. A., Jongsma, K. R. & Bredenoord, A. L. Mini-gut feelings: Perspectives of people with cystic fibrosis on the ethics and governance of organoid biobanking. Pers. Med. 18, 241–254. https://doi.org/10.2217/pme-2020-01 (2021).

    Article 

    Google Scholar     

    • Mercato Announces Launch of Thriving Communities Program, eCommerce Platform Increases Healthy Food Access and Grows Small Businesses in Low-Income Communities

    Initial roll-out in New York City proves program increases sales for the independent grocer while providing residents with greater choice and convenience. Platform can accelerate online SNAP purchases and provide other healthy food incentives.

    SAN DIEGO, Nov. 21, 2022 /PRNewswire/ — Mercato, the nation’s leading eCommerce platform for independent grocers, has announced its new initiative to improve access to healthy foods and foster economic stability in low-income communities.

    Thriving Communities works with local governments, private funders and non-profits to bring more grocers onto the eGrocery platform so they can digitize their inventory, offer delivery and enable enrollment and utilization of SNAP online.

    It creates what founder and CEO Bobby Brannigan calls “The Mercato Effect” – whereby grocers going online provides residents access to healthy, culturally appropriate foods and the ability to redeem public/private food benefits which in turn creates more jobs, increases grocers’ sales and keeps dollars circulating within the community.

    “As the son of an independent grocer in Brooklyn, I know first-hand how critical these independent, local grocers are to the economic and social well-being of their communities,” said Brannigan. “They are the lifeline for so many residents to get fresh, healthy, culturally relevant foods without having to travel far or wait weeks to go to the market. By giving local grocers the tools and technologies to operate online, they can increase their own revenue and fuel healthier ecosystems throughout the country.”

    New York City was the first city to partner with Mercato, leveraging Thriving Communities to test a technological pilot that offered subsidized groceries to a cohort of New Yorkers.

    “The pandemic challenged food security in unprecedented ways,” said Kate MacKenzie, executive director, New York City Mayor’s Office of Food Policy. “Mercato’s innovative work piloting online grocery benefits making healthy, affordable groceries accessible to all New Yorkers, no matter where they live. New York City is proud to innovate with technology and public benefits, and we are thrilled that Mercato recognizes this too.”

    “Getting onto the Mercato platform was game-changing for our store and our shoppers,” said Gustavo Rodriguez of Key Food Stadium, located in the Bronx. “Our sales are increasing literally every day, especially fresh produce, and the technology and service Mercato provides enables us to fulfill orders seamlessly and with the same personal attention and care that our shoppers need and deserve. It feels incredible to be feeding and helping low-income residents in our community.”

    Mercato is looking to expand Thriving Communities by finding and collaborating with partners in other cities including Chicago, Boston, Baltimore, Philadelphia and Los Angeles.

    For more about Mercato Thriving Communities, the impact it can have and how to get involved visit www.mercato.com/thrive

    About Mercato

    Mercato is an eCommerce and local delivery platform that provides thousands of independent grocers across the country with the tools and technologies they need to stay competitive in the marketplace. Headquartered in San Diego, CA, it was founded by Bobby Brannigan, the son of a neighborhood grocer in Brooklyn, who saw his father needed to modernize his inventory and delivery systems to stay in business and better serve his shoppers. Since launching in 2015 Mercato has brought more than 1,500 stores across the country onto the platform.

    Press Contact:  Richard Shea, Shea Communications (917) 584-3542

    Cision

    Cision

    View original content to download multimedia:https://www.prnewswire.com/news-releases/mercato-announces-launch-of-thriving-communities-program-ecommerce-platform-increases-healthy-food-access-and-grows-small-businesses-in-low-income-communities-301683852.html

    SOURCE Mercato